Search
Camptothecin
go.drugbank.com/drugs/DB04690InvestigationalCamptothecin is an alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA topoisomerase, type I. Several semisynthetic analogs of camptothecin have demon...
Deferitazole
go.drugbank.com/drugs/DB13120InvestigationalIt has been used in trials studying the treatment and basic science of Beta-thalassemia, Hepatic Impairment, Impaired Renal Function, Transfusional Iron Overload, and Iron Overload Due to Repeated Red
Lobeline
go.drugbank.com/drugs/DB05137InvestigationalIt has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral vascular disorders, insomnia, and smoking cessation. [PubChem]
Human umbilical cord blood mononuclear cell-conditioned medium
go.drugbank.com/drugs/DB15724ExperimentalTransplantation with human umbilical cord blood mononuclear cells (HUCBC) has demonstrated promising results in various disease states. While some of the positive results are credited to HUCBCs’ differentiation potential, the growth fact...
KAND567
go.drugbank.com/drugs/DB16511InvestigationalKAND567, a small molecule, blocks the fractaline (CX3CL1) receptor, which mediates the immune system response to inflammation . Because COVID-19 involves cytotoxic cells associated with this pathway, KAND567 is currently being tested as ...
OXI-4503
go.drugbank.com/drugs/DB05143InvestigationalOXI-4503 is investigated in clinical trials for treating cancer/tumors. OXI-4503 is a solid. OXI-4503 blocks and destroys tumor vasculature, resulting in extensive tumor cell death and necrosis. OXI-4503 (combretastatin A1 di-phosphate /...
Tobramycin
go.drugbank.com/drugs/DB00684ApprovedInvestigational[L32744, L32749] Its use is limited in some cases by characteristic toxicities such as nephrotoxicity and ototoxicity, yet it remains a valuable option in the face of growing resistance to front-line antibiotics
Delandistrogene moxeparvovec
go.drugbank.com/drugs/DB16802ApprovedInvestigationalIt was granted accelerated approval by the FDA on June 22, 2023, as the first gene therapy to treat Duchenne Muscular Dystrophy (DMD).